TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6783346
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 20 mg as an aerosol
Study: 17877506
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy options
Study: 10404803
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg 4 times daily for 8 weeks
Study: 26887207
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received lower dose anesthetics (Fentanyl 250 μg + Flurbiprofen axetil 25 mg + normal saline 2 mL/h, Sauteralgyl if necessary)
Study: 21949005
Drug: Target treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target treatment group (2 hours of therapy and coaching each week)
Study: 21949005
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment group (variety of services averaging 3.9 hours per week)
Study: 21949005
Drug: Target treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target treatment group
Study: 19702088
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI) after surgical operation and chemotherapy (group C)
Study: 14561016
Drug: Cardioselective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioselective beta-blockers (single dose)
Study: 14561016
Drug: Cardioselective beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioselective beta-blockers (longer duration)
Study: 10898408
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (50 mg) plus ISMN (20 mg twice a day)
Study: 10898408
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (50 mg) plus GTN (500 microg)
Study: 10898408
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus ISMN (20 mg twice a day)
Study: 8599314
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (153 micromol or 10 mg Zn/d)
Study: 2856902
Drug: Nadolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (40 mg twice a day)
Study: 31113277
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (mean dose: 622.0 mg/day)
Study: 17445921
Drug: Adjunctive corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive corticosteroids (used by 109 patients, 58.9%)
Study: 17445921
Drug: Non-use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-use of adjunctive corticosteroids
Study: 8732558
Drug: Mother's own
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mother's own milk with multivitamin supplement with iron
Study: 6613525
Drug: Gamma-vinyl-GABA (GVG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-vinyl-GABA (GVG) 1 g per day
Study: 6613525
Drug: Gamma-vinyl-GABA (GVG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-vinyl-GABA (GVG) 2 g per day
Study: 6613525
Drug: Gamma-vinyl-GABA (GVG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-vinyl-GABA (GVG) 3 g per day
Study: 29908417
Drug: Nilotinib (NIL)
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib (NIL) 800 mg/day (Cohort 1)
Study: 29908417
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (IM) 800 mg/day (Cohort 2)
Study: 29908417
Drug: Sustained standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained standard-dose imatinib (IM) 400 mg/day (Cohort 3)
Study: 27502710
Drug: Standard paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard paclitaxel at 200 mg/m(2) (arm A)
Study: 27502710
Drug: PK-guided dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK-guided dosing of paclitaxel (arm B)
Study: 24833327
Drug: High-dose N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose N-acetylcysteine (NAC) 600 mg bid
Study: 18813043
Drug: Low-dose dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexmedetomidine (loading, 3 microg x kg(‐1) x h(‐1) for 10 min; maintenance, 0.2 microg x kg(‐1) x h(‐1) for 60 min)
Study: 18813043
Drug: High-dose dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexmedetomidine (loading, 6 microg x kg(‐1) x h(‐1) for 10 min; maintenance, 0.4 microg x kg(‐1) x h(‐1) for 60 min)
Study: 11968583
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha monotherapy (3 million u. three times per week until signs of relapse)
Study: 11968583
Drug: Sequence administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequence administration of interferon alpha and dexamethasone (40 mg on days 1-4, 10-13, and 20-23, followed by interferon alpha after a four-week interval until disease progression)
Study: 11968583
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha monotherapy or dexamethasone (preference question)
Study: 11968583
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment overall
Study: 2181588
Drug: Levodopa (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (mean dose: 485 ± 71 mg daily)
Study: 2181588
Drug: Bromocriptine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (mean dose: 55 ± 6 mg daily)
Study: 394755
Drug: Aminophylline suppositories
Normalized name: Aminophylline Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline suppositories
Study: 394755
Drug: Slow-release aminophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release aminophylline tablets
Study: 30821115
Drug: DP-VPA 1200
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DP-VPA 1200 mg
Study: 25678838
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic with steroid with lumbar interlaminar approach
Study: 25678838
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic with steroid with caudal approach
Study: 17298590
Drug: Self-management-oriented programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management-oriented programme (treatment B)
Study: 17298590
Drug: Didactic‐oriented training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didactic‐oriented training programme (treatment A)
Study: 17298590
Drug: More individualized
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More individualized approach (treatment C)
Study: 11220982
Drug: Sildenafil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (all doses combined)
Study: 8821690
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin acetate (3.6 mg every 28 days)
Study: 8821690
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (300 mg/day)
Study: 8821690
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of goserelin acetate and cyproterone acetate
Study: 1444298
Drug: Teicoplanin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (100 mg twice a day for 10 days)
Study: 6138597
Drug: Vancomycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (500 mg four times a day for 10 days)
Study: 26879791
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Finasteride + Tamsulosin)
Study: 20454855
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) d,l-MPH 20 mg
Study: 20454855
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) d,l-MPH 20 mg
Study: 17432644
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of pepsin mixture
Study: 11851868
Drug: Cerivastatin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.2 mg daily for 6 weeks, then increased to 0.4 mg if LDL-C did not decrease below 3.0 mmol x L(-1))
Study: 11851868
Drug: Fenofibrate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (250 mg daily)
Study: 9861907
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention program (early surgery, minimal narcotic analgesia, intense daily therapy, close monitoring)
Study: 7595907
Drug: Fludrocortisone 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 0.8 mg daily for 7 days (short protocol)
Study: 7595907
Drug: Fludrocortisone (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (1.4 nmol/l) in vitro
Study: 7595907
Drug: Fludrocortisone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone treatment
Study: 21118281
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg intravenously)
Study: 19489487
Drug: Electroacupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture at Fenglong (ST 40) with parameters: 50 Hz, 1 mA for TG type (20 min, twice/week); 100 Hz, 1 mA for CHO type (30 min, thrice/week); same as CHO for LDL-C type; alternating methods for mixing type.
Study: 19489487
Drug: Xuezhikang capsule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang capsule, 2 capsules twice daily for 11 weeks.
Study: 8192275
Drug: 2 grams
Normalized name: phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams of oral vitamin C for one month
Study: 29689025
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR) monotherapy
Study: 22049798
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/d for 30 days
Study: 16527402
Drug: Replacement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replacement of baseline health-state-related measures with post-treatment measures
Study: 8612391
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg moclobemide
Study: 8612391
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of entacapone and moclobemide
Study: 6443775
Drug: Reference antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference antibiotics (gentamicin, tobramycin, amikacin, or ticarcillin)
Study: 6443775
Drug: Reference antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference antibiotics
Study: 6443775
Drug: Cefsulodin or
Normalized name: cefsulodin
DrugBank: Cefsulodin (DB13499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefsulodin or reference antibiotics
Study: 21415134
Drug: Combination antithrombotic
Normalized name: ANTITHROMBIN III,RECOMBINANT
DrugBank: Antithrombin Alfa (DB11166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antithrombotic therapy (subcutaneous idraparinux 2.5 mg weekly + antiplatelet therapy)
Study: 21415134
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy only (dose-adjusted vitamin K antagonists)
Study: 21415134
Drug: Combination antithrombotic
Normalized name: ANTITHROMBIN III,RECOMBINANT
DrugBank: Antithrombin Alfa (DB11166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antithrombotic therapy
Study: 18502255
Drug: UV irradiation
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV irradiation (suberythemal doses, twice weekly for 12 weeks)
Study: 16553686
Drug: Customized exercise
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized exercise programme (12-month programme of cardiorespiratory, stretching, muscle-strengthening and relaxation exercises, 2 sessions per week, total of 3 hours weekly)
Study: 8446047
Drug: Hypocaloric glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric glucose infusion
Study: 3097383
Drug: Intravenous 100
Normalized name: immune globulin intravenous 100 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 100 micrograms of human corticotropin-releasing factor
Study: 29423501
Drug: Sulindac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (150 mg twice daily) and Erlotinib (75 mg daily)
Study: 24057928
Drug: SEQ-FLUOX (fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEQ-FLUOX (fluoxetine 20mg, starting 8 weeks before quit date and continuing for 8 weeks after quit date + TNP)
Study: 24057928
Drug: ST-FLUOX (fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST-FLUOX (fluoxetine 20mg, starting 2 weeks before quit date and continuing for 8 weeks after quit date + TNP)
Study: 20013016
Drug: Micafungin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin therapy
Study: 18595990
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 400 mug of cobalamin
Study: 11413538
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (vincristine, actinomycin-D, cyclophosphamide - VAC)
Study: 11413538
Drug: IRS-III/IV treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRS-III/IV treatments
Study: 11413538
Drug: IRS-I/II treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRS-I/II treatments
Study: 11413538
Drug: Local therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local therapy (surgery and RT)
Study: 9001297
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 50 microg every 12 h
Study: 9001297
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline (individually dose‐titrated sustained-release)
Study: 8394627
Drug: Erythromycin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (0.5 g b.i.d.)
Study: 27118206
Drug: Increase of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase of daily GH dose (IGF-1 target level of 1 to 2 SDS)
Study: 27118206
Drug: Decrease of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease of daily GH dose (IGF-1 target level of -2 to -1 SDS)
Study: 19298639
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) administration of darbepoetin alfa
Study: 19298639
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of darbepoetin alfa
Study: 19298639
Drug: Both s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both s.c. and i.v. administration of darbepoetin alfa
Study: 8392826
Drug: Granisetron tablet
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron tablet (2 mg)
Study: 3107546
Drug: Prazosin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin therapy (1 to 8 mg/day for 8 weeks)
Study: 3107546
Drug: Propranolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol therapy (20 to 240 mg/day for 8 weeks)
Study: 29220885
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with disease‐modifying drugs and MEB
Study: 29220885
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy using MEB medication and iron
Study: 26969836
Drug: Lettuce juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lettuce juice beverage containing approximately 200 mg nitrate per day (test)
Study: 20627979
Drug: 225 IU
Normalized name: Ascorbic Acid/Calcium Pantothenate/Cyanocobalamin/Iron/Niacin/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin D/Vitamin E/Zinc 200 MG-18.4 MG-0.005 MG-12 MG-100 MG-4.1 MG-10 MG-0.3 MG-10000 IU-400 IU-225 IU-1.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 IU starting dose of recombinant FSH (r‐FSH)
Study: 20627979
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU starting dose of recombinant FSH (r‐FSH)
Study: 19120955
Drug: Current American
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current American Board of Internal Medicine Mini-CEX form
Study: 21775910
Drug: 530 mg
Normalized name: citric acid 1530 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 530 mg of concentrated valerian extract twice a day for 4 weeks
Study: 9855317
Drug: Fasting conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting conditions (PZA 30 mg/kg)
Study: 9855317
Drug: Antacids (PZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (PZA 30 mg/kg)
Study: 9855317
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (PZA 30 mg/kg)
Study: 3289717
Drug: Alprazolam (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (2.4 mg average daily dose)
Study: 3289717
Drug: Amitriptyline hydrochloride
Normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride (135 mg average daily dose)
Study: 27632863
Drug: Static stretching
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static stretching (SS) program performed 3 times weekly for 4 weeks
Study: 1381210
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg per day of medroxyprogesterone acetate (MPA)
Study: 1381210
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen (cisplatin, 5‐fluorouracil, methotrexate, bleomycin, vincristine)
Study: 25157723
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of blood pressure combined with an individualized self-titration algorithm.
Study: 25157723
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (routine blood pressure measurement and adjustment of medication if necessary).
Study: 25157723
Drug: Self-monitoring with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring with self-titration of antihypertensive medication.
Study: 23737510
Drug: mirtazapine 30
Normalized name: mirtazapine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirtazapine 30 mg/day
Study: 23737510
Drug: mirtazapine 15
Normalized name: mirtazapine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirtazapine 15 mg/day
Study: 17492340
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (7 sessions of IPL, 9 sessions of low intense diode light, and biostimulation by drugs)
Study: 17492340
Drug: Monotherapy (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (7 sessions of IPL only)
Study: 17213792
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg per os on demand for 3 months (Group A)
Study: 17213792
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg per os on weekly fixed days (Monday‐Wednesday‐Friday) for 3 months (Group B)
Study: 11422338
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) 50-600 mg/day
Study: 8508556
Drug: Prednisone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (30 mg, alternate days)
Study: 8508556
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg, daily)
Study: 2950827
Drug: PDC-HDC diacetate
Normalized name: Diflorasone Diacetate
DrugBank: Diflorasone (DB00223)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDC-HDC diacetate (306.5 mg over five weeks, followed by 960 mg during maintenance)
Study: 27076209
Drug: Memantine (MEM)
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Memantine (MEM) 20 mg p.o.
Study: 24722932
Drug: Telemonitoring (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemonitoring (daily measuring of health parameters including ECG, blood pressure, weight, and self-assessment)
Study: 14710772
Drug: 1.0% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% chlorhexidine gel (Period C)
Study: 10910607
Drug: MMR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR and JE vaccines nonsimultaneously (Group A)
Study: 10910607
Drug: MMR and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR and JE vaccines simultaneously (Group B)
Study: 1699597
Drug: Cornflakes (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornflakes (350 g/d, providing 10.33 g RS/d)
Study: 1699597
Drug: Rice Krispies
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice Krispies (380 g/d, providing 0.86 g RS/d)
Study: 7365045
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (exposure + response prevention) for 2 weeks after initial treatments